ONE-WAYDated event · through FY2027-H1
Acquisition of exclusive development and marketing rights in Japan for EB05
An individual licensing-in opportunity under which exclusive development and marketing rights in Japan for EB05, a treatment candidate for ARDS, were acquired from Edesa, with domestic commercialization to proceed in exchange for an upfront payment and development and sales milestones.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2027-H1 →Last written FY2027-H1
Directionhelps1 helps · 0 hurts · 0 flat